--- title: "Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT" type: "News" locale: "en" url: "https://longbridge.com/en/news/295510829.md" description: "Hennion & Walsh Asset Management Inc. increased its stake in Phathom Pharmaceuticals (PHAT) by 124.3% to $3.55 million in Q2. Other institutions like Millennium Management and Invesco also significantly increased holdings, with institutional investors owning 99.01% of the stock. Analyst ratings remain mixed but lean 'Moderate Buy' with an average target of $23.43, despite recent price target cuts from Needham and Guggenheim." datetime: "2026-08-11T09:13:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295510829.md) - [en](https://longbridge.com/en/news/295510829.md) - [zh-HK](https://longbridge.com/zh-HK/news/295510829.md) --- # Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT Hennion & Walsh Asset Management Inc. increased its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 124.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 327,278 shares of the company's stock after purchasing an additional 181,346 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.41% of Phathom Pharmaceuticals worth $3,551,000 at the end of the most recent quarter. Several other hedge funds have also bought and sold shares of the business. Millennium Management LLC raised its holdings in Phathom Pharmaceuticals by 125.8% during the third quarter. Millennium Management LLC now owns 5,081,451 shares of the company's stock worth $59,809,000 after buying an additional 2,830,954 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of Phathom Pharmaceuticals during the first quarter valued at about $10,277,000. EcoR1 Capital LLC bought a new stake in shares of Phathom Pharmaceuticals during the first quarter worth about $6,944,000. Moore Capital Management LP bought a new stake in shares of Phathom Pharmaceuticals during the second quarter worth about $5,754,000. Finally, Invesco Ltd. increased its position in shares of Phathom Pharmaceuticals by 13.4% during the second quarter. Invesco Ltd. now owns 4,140,072 shares of the company's stock worth $39,703,000 after acquiring an additional 489,260 shares in the last quarter. Institutional investors and hedge funds own 99.01% of the company's stock. ## Analyst Upgrades and Downgrades Several equities analysts recently weighed in on the stock. Needham & Company LLC dropped their price target on shares of Phathom Pharmaceuticals from $28.00 to $22.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Guggenheim decreased their price objective on Phathom Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Friday, July 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a research note on Friday, July 17th. Craig Hallum restated a "buy" rating and issued a $20.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, July 31st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Phathom Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $23.43. **Check Out Our Latest Research Report on PHAT** ## Phathom Pharmaceuticals Stock Up 0.2% Shares of NASDAQ PHAT opened at $8.57 on Tuesday. The company has a market capitalization of $693.31 million, a PE ratio of -6.70 and a beta of 0.51. The stock's 50 day moving average price is $10.55 and its 200-day moving average price is $11.42. Phathom Pharmaceuticals, Inc. has a twelve month low of $8.21 and a twelve month high of $18.31. ## Phathom Pharmaceuticals Company Profile (Free Report) Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist. The company's lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States. ## Featured Articles - Five stocks we like better than Phathom Pharmaceuticals - SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat - 3 Dividend Champion Utilities for a Market That Can't Sit Still - These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI - First Solar’s Profit Engine Faces a New Policy Test in Washington _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Phathom Pharmaceuticals Right Now? Before you consider Phathom Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list. While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PHAT.US](https://longbridge.com/en/quote/PHAT.US.md) - [IVZ.US](https://longbridge.com/en/quote/IVZ.US.md) - [SOUN.US](https://longbridge.com/en/quote/SOUN.US.md) - [FSLR.US](https://longbridge.com/en/quote/FSLR.US.md) - [SOUNW.US](https://longbridge.com/en/quote/SOUNW.US.md) ## Related News & Research - [Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growth](https://longbridge.com/en/news/294353778.md) - [Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2% - What's Next?](https://longbridge.com/en/news/296523524.md) - [39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP](https://longbridge.com/en/news/296452266.md) - [Bank of America Corp DE Sells 85,189 Shares of Crinetics Pharmaceuticals, Inc. $CRNX](https://longbridge.com/en/news/296069006.md) - [612,850 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by SCS Capital Management LLC](https://longbridge.com/en/news/296022218.md)